查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612655

脑肿瘤和脊髓癌市场：按肿瘤类型、治疗和最终用户划分 - 全球预测 2025-2030

Brain & Spinal Cord Cancer Market by Tumor Type (Glioblastoma, Meningioma, Pituitary Tumors), Treatment (Diagnosis, Therapeutics), End-users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑瘤和脊髓癌市值为37.7亿美元，预计到2024年将达到39.8亿美元，复合年增长率为5.75%，到2030年将达到55.9亿美元。

脑肿瘤和脊髓癌市场范围涵盖中枢神经系统恶性的诊断、治疗和研究的各个方面。由于其位置关键且复杂，这些疾病通常需要专门的治疗方法。由于目前的治疗选择仍然有限，提高生存率和生活品质的迫切需求推动了对先进治疗和早期诊断工具的需求。应用范围从传统的手术和放射治疗到创新的标靶治疗和个人化医疗。最终使用者包括医院、专门的癌症治疗中心和研究机构。影响该市场的主要成长要素包括发病率上升、分子生物学的进步带来新的治疗方法，以及政府和私营部门对肿瘤学研究的大量投资。液态切片和先进成像技术等非侵入性诊断技术的发展为早期检测和客製化治疗计划提供了希望。生物技术公司和学术机构之间的合作也刺激了该领域的创新。然而，它受到一些限制的挑战，包括高昂的研发成本、严格的监管要求以及中枢神经系统肿瘤的复杂性质，使治疗方法变得复杂。此外，市场也面临专业医护人员的短缺，影响了护理服务。策略建议包括专注于开发具有成本效益的治疗方法、透过伙伴关係关係提高患者获得最先进治疗的机会，以及投资专业卫生专业人员的培训计划。创新领域包括免疫疗法、CRISPR等基因编辑技术以及人工智慧在个人化治疗和药物发现的应用。该市场的特点是竞争激烈、节奏快，需要不断创新并适应新技术进步，以保持相关性并抓住成长机会。

主要市场统计
基准年[2023] 37.7亿美元
预计年份 [2024] 39.8亿美元
预测年份 [2030] 55.9亿美元
复合年增长率（%） 5.75%

市场动态：针对快速发展的脑肿瘤和脊椎癌市场揭示的关键市场见解

供需的动态交互作用正在改变脑肿瘤和脊髓癌症市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球脑癌和脊髓癌盛行率上升
    • 由于人们对这些疾病的认识提高，对医疗基础设施的投资增加
    • 政府继续努力进行癌症研究和早期检测
  • 市场限制因素
    • 脑癌和脊髓癌的治疗费用高昂且获得先进医疗设施的机会有限
  • 市场机会
    • 在诊断过程中引入人工智慧和机器学习
    • 人们越来越偏好基于基因图谱的个人化医疗
  • 市场挑战
    • 对脑癌和脊髓癌复杂性的担忧

波特五力：驾驭脑瘤和脊椎癌市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对脑肿瘤和脊髓癌市场的影响

外部宏观环境因素在塑造脑肿瘤和脊髓癌症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解脑肿瘤/脊髓癌市场的竞争状况

脑肿瘤和脊椎癌市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脑瘤和脊椎癌市场供应商的绩效评估

FPNV 定位矩阵是评估脑肿瘤和脊椎癌市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製脑肿瘤和脊髓癌市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，脑肿瘤和脊髓癌市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球脑和脊髓肿瘤的发生率增加
      • 随着人们对这些疾病的认识不断提高，对医疗保健基础设施的投资也增加
      • 政府继续努力进行癌症研究和早期检测
    • 抑制因素
      • 脑癌和脊髓癌的治疗费用很高，并且获得先进医疗设施的机会有限。
    • 机会
      • 将人工智慧和机器学习纳入诊断过程
      • 人们对基于基因图谱的个人化医疗越来越感兴趣
    • 任务
      • 对脑癌和脊髓癌复杂性的担忧
  • 市场区隔分析

第 5 章 2.1。

第 5 章 2.2。

  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依肿瘤类型分類的脑肿瘤/脊髓癌市场

  • 神经胶母细胞瘤
  • 脑膜瘤
  • 脑下垂体瘤

第七章依治疗分類的脑肿瘤/脊髓癌市场

  • 诊断
    • 脑动脉造影
    • 电脑断层扫描
    • 脑电波
    • 腰椎穿刺
    • 分子检测
    • MRI
    • PET- 电脑断层扫描
    • 组织样本采集
  • 治疗药物
    • 化疗
    • 免疫疗法
    • 放射治疗
    • 外科手术
    • 标靶治疗

第 8 章 脑肿瘤/脊髓癌市场：依最终用户划分

  • 门诊手术中心
  • 诊断中心
  • 医院/诊所

第九章北美和南美脑肿瘤和脊髓癌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区脑肿瘤与脊髓癌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的脑肿瘤和脊髓癌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Diaconos 的脑肿瘤疫苗获得 FDA 孤儿药称号
    • 诺华公司的 Tafinlar + Mekinist 已获得 FDA核准用于患有 BRAF V600E 低恶性神经胶质瘤（最常见的儿童脑瘤）的儿科患者。
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S
Product Code: MRR-9E71DF483B96

The Brain & Spinal Cord Cancer Market was valued at USD 3.77 billion in 2023, expected to reach USD 3.98 billion in 2024, and is projected to grow at a CAGR of 5.75%, to USD 5.59 billion by 2030.

The scope of the brain and spinal cord cancer market encompasses various aspects of diagnosis, treatment, and research related to malignant tumors located within the central nervous system. These conditions often require specialized therapeutic approaches due to their critical location and complexity. The necessity for advanced treatments and early diagnostic tools is driven by the dire need to improve survival rates and quality of life, as current therapeutic options remain limited. Applications span from conventional surgical and radiotherapeutic interventions to innovative targeted therapies and personalized medicine. End-users include hospitals, specialized cancer treatment centers, and research institutions. Key growth factors influencing this market include increasing incidence rates, advancements in molecular biology leading to novel therapeutic approaches, and significant governmental and private sector investments in oncology research. A notable opportunity lies in the development of non-invasive diagnostic technologies, such as liquid biopsies and advanced imaging techniques, which promise earlier detection and tailored treatment plans. Collaborations between biotechnology firms and academic institutions are also spurring innovation in this domain. However, several limitations present challenges, such as the high cost of research and development, stringent regulatory requirements, and the complex nature of central nervous system tumors which complicates treatment approaches. Additionally, the market faces a shortage of specialized healthcare professionals, affecting the delivery of care. Strategic recommendations include focusing on the development of cost-effective therapies, enhancing patient access to cutting-edge treatments through partnerships, and investing in training programs for specialized healthcare providers. Innovative areas ripe for exploration include immunotherapy, gene editing technologies like CRISPR, and the application of AI in treatment personalization and drug discovery. The market is characterized by high competition and a fast-paced environment, necessitating continuous innovation and adaptation to emerging technological advancements to maintain relevance and capture growth opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 3.77 billion
Estimated Year [2024] USD 3.98 billion
Forecast Year [2030] USD 5.59 billion
CAGR (%) 5.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain & Spinal Cord Cancer Market

The Brain & Spinal Cord Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of brain and spinal cord cancers globally
    • Increased investment in healthcare infrastructure with growing awareness about these conditions
    • Ongoing government initiatives aimed at cancer research and early detection
  • Market Restraints
    • High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer
  • Market Opportunities
    • Incorporation of AI and machine learning in diagnostic processes
    • Increasing preference for personalized medicine based on genetic profile
  • Market Challenges
    • Concerns associated with the complex nature of brain and spinal cord cancers

Porter's Five Forces: A Strategic Tool for Navigating the Brain & Spinal Cord Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain & Spinal Cord Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain & Spinal Cord Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain & Spinal Cord Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain & Spinal Cord Cancer Market

A detailed market share analysis in the Brain & Spinal Cord Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain & Spinal Cord Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain & Spinal Cord Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain & Spinal Cord Cancer Market

A strategic analysis of the Brain & Spinal Cord Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain & Spinal Cord Cancer Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bayer AG, bluebird bio, Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eisai Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc., Nektar Therapeutics, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shimadzu Corporation, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., and Y-mAbs Therapeutics A/S.

Market Segmentation & Coverage

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Tumor Type, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.
  • Based on Treatment, market is studied across Diagnosis and Therapeutics. The Diagnosis is further studied across Cerebral Arteriogram, CT Scan, EEG, Lumbar Puncture, Molecular Testing, MRI, PET-CT Scan, and Tissue Sampling. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on End-users, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, and Hospital & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of brain and spinal cord cancers globally
      • 5.1.1.2. Increased investment in healthcare infrastructure with growing awareness about these conditions
      • 5.1.1.3. Ongoing government initiatives aimed at cancer research and early detection
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Incorporation of AI and machine learning in diagnostic processes
      • 5.1.3.2. Increasing preference for personalized medicine based on genetic profile
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the complex nature of brain and spinal cord cancers
  • 5.2. Market Segmentation Analysis

5.2.1. Treatment:

5.2.2. End-users:

  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain & Spinal Cord Cancer Market, by Tumor Type

  • 6.1. Introduction
  • 6.2. Glioblastoma
  • 6.3. Meningioma
  • 6.4. Pituitary Tumors

7. Brain & Spinal Cord Cancer Market, by Treatment

  • 7.1. Introduction
  • 7.2. Diagnosis
    • 7.2.1. Cerebral Arteriogram
    • 7.2.2. CT Scan
    • 7.2.3. EEG
    • 7.2.4. Lumbar Puncture
    • 7.2.5. Molecular Testing
    • 7.2.6. MRI
    • 7.2.7. PET-CT Scan
    • 7.2.8. Tissue Sampling
  • 7.3. Therapeutics
    • 7.3.1. Chemotherapy
    • 7.3.2. Immunotherapy
    • 7.3.3. Radiation Therapy
    • 7.3.4. Surgery
    • 7.3.5. Targeted Therapy

8. Brain & Spinal Cord Cancer Market, by End-users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Diagnostic Centers
  • 8.4. Hospital & Clinics

9. Americas Brain & Spinal Cord Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Brain & Spinal Cord Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Brain & Spinal Cord Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Diakonos' brain tumor vaccine receives FDA's orphan drug designation
    • 12.3.2. Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Bayer AG
  • 3. bluebird bio, Inc.
  • 4. Bristol Myers Squibb Company
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Eisai Inc.
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Genentech, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Illumina, Inc.
  • 11. Johnson & Johnson Services, Inc
  • 12. Merck & Co., Inc.
  • 13. Nektar Therapeutics
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Shimadzu Corporation
  • 18. Siemens Healthineers
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Y-mAbs Therapeutics A/S

LIST OF FIGURES

  • FIGURE 1. BRAIN & SPINAL CORD CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN & SPINAL CORD CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN & SPINAL CORD CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CEREBRAL ARTERIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EEG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PET-CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TISSUE SAMPLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 242. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 243. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2023